The U.S. Food and Drug Administration announced the Global Reliance Disclosure Program, a new effort to let other countries use the agency’s drug and biologic approval decisions to speed patient access to medicines, according to the FDA.
The program allows the FDA to share minimally redacted approval packages, including scientific and regulatory assessments, with companies that can then provide them to foreign health authorities. The FDA said this can help regulators abroad rely on the agency’s reviews instead of repeating full product evaluations, while keeping their own decision-making authority.
The FDA said the Global Reliance Disclosure Program, or GRDP, began on Oct. 30 with a President’s Emergency Plan for AIDS Relief tentative approval for lenacapavir, which is indicated for HIV prevention and treatment. The agency described this as a meaningful start because of PEPFAR’s mission to combat HIV/AIDS. The FDA said the program now applies to PEPFAR tentative approvals, but not to tentatively approved abbreviated new drug applications.
The agency said it intends to expand the GRDP in January 2027 to all novel drugs and biologics, including New Molecular Entity New Drug Applications and 351(a) Biologics License Applications. The FDA also said it intends to launch a pathway in early 2027 to speed applicants’ requests for minimally redacted action packages for already approved and licensed drugs and biologics in the United States.
Applicants seeking a minimally redacted approval package under the GRDP must ask to participate within 10 calendar days after approval and confirm that the package will be submitted to a non-U.S. regulator to support a marketing application, the FDA said. The agency said eligible applicants will receive details in their approval letters and that it intends to provide the packages on an expedited basis. The FDA said requests for such approval packages for any other use are outside the GRDP and must be filed through the Freedom of Information Act process.
The FDA said the GRDP aims to narrow the gap between approvals in high-capacity countries and patient access in lower-resource settings, where independent reviews can take months or years. The agency said it also supports global health security by encouraging consistent product standards across markets.